Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cogent Biosciences (Nasdaq: COGT), a biotechnology company specializing in precision therapies, has granted inducement equity awards to 10 new employees. The Compensation Committee approved options to purchase 299,200 shares of common stock under the company's 2020 Inducement Plan on September 29, 2025.
The options feature a 10-year term with a four-year vesting schedule, including 25% vesting after one year and the remainder vesting monthly over 36 months. The exercise price equals Cogent's closing stock price on the grant date, subject to continued employment through vesting dates.
Cogent Biosciences (Nasdaq: COGT), un'azienda biotecnologica specializzata in terapie di precisione, ha concesso premi azionari di incentivazione a 10 nuovi dipendenti. Il Comitato per la Retribuzione ha approvato opzioni per l'acquisto di 299.200 azioni ordinarie ai sensi del piano di incentivazione 2020 dell'azienda in data 29 settembre 2025.
Le opzioni hanno una durata di 10 anni con un piano di vesting quadriennale, con il 25% che matura dopo un anno e il resto che matura mensilmente nei 36 mesi successivi. Il prezzo di esercizio è uguale al prezzo di chiusura delle azioni Cogent alla data di concessione, soggetto al mantenimento dell'impiego fino alle date di vesting.
Cogent Biosciences (Nasdaq: COGT), una compañía de biotecnología especializada en terapias de precisión, ha otorgado premios de acciones de incentivo a 10 nuevos empleados. El Comité de Compensación aprobó opciones para comprar 299.200 acciones ordinarias bajo el Plan de Incentivos 2020 de la empresa el 29 de septiembre de 2025.
Las opciones tienen un plazo de 10 años con un calendario de vesting de cuatro años, con un 25% de vesting al completar un año y el resto vesting mensual durante 36 meses. El precio de ejercicio es igual al precio de cierre de las acciones de Cogent en la fecha de concesión, sujeto a la continuidad en el empleo hasta las fechas de vesting.
Cogent Biosciences (Nasdaq: COGT), 정밀 의약품을 전문으로 하는 생명공학 회사는 새로운 10명 직원에게 유인 주식 보상을 부여했습니다. 보상 위원회는 2025년 9월 29일 회사의 2020년 유인 계획에 따라 공통 주식 299,200주를 매수할 수 있는 옵션을 승인했습니다.
옵션은 10년 기한이며 4년의 가정 일정으로 구성되어 있으며, 1년 후 25%가 베스팅되고 나머지는 36개월간 매월 베스팅됩니다. 행사가격은 부여일의 Cogent 종가와 같고, 베스팅 날짜까지 고용 유지가 전제됩니다.
Cogent Biosciences (Nasdaq: COGT), une entreprise de biotechnologie spécialisée dans les thérapies de précision, a accordé des actions d'incitation à 10 nouveaux employés. Le Comité de rémunération a approuvé des options d'achat pour 299 200 actions ordinaires dans le cadre du Plan d'incitation 2020 de l'entreprise le 29 septembre 2025.
Les options présentent une durée de 10 ans avec un calendrier de vesting sur quatre ans, dont 25% se vestent après un an et le reste se vest mensuellement sur 36 mois. Le prix d'exercice est égal au cours de clôture de Cogent à la date d'attribution, sous réserve du maintien de l'emploi jusqu'aux dates de vesting.
Cogent Biosciences (Nasdaq: COGT), ein Biotechnologieunternehmen, das sich auf Präzisions-Therapien spezialisiert hat, hat 10 neue Mitarbeiter mit Incentive-Aktien belohnt. Der Vergütigungsausschuss genehmigte Optionen zum Erwerb von 299.200 Stammaktien gemäß dem 2020 Incentive Plan des Unternehmens am 29. September 2025.
Die Optionen haben eine Laufzeit von 10 Jahren mit einem Vesting-Plan über vier Jahre, wobei 25% nach einem Jahr vesten und der Rest in monatlichen Raten über 36 Monate vestet. Der Ausübungspreis entspricht dem Schlusskurs der Cogent-Aktien am Ausgabetag, vorbehaltlich einer fortgesetzten Beschäftigung bis zu den Vesting-Daten.
Cogent Biosciences (Nasdaq: COGT)، شركة التكنولوجيا الحيوية المتخصصة في العلاجات الدقيقة، منحت مكافآت أسهم حافزية لـ عشرة موظفين جدد. وافق لجنة التعويض على خيارات لشراء 299,200 سهم عادي بموجب خطة التحفيز لعام 2020 الخاصة بالشركة في 29 سبتمبر 2025.
وتتضمن الخيارات مدة صلاحية تبلغ 10 سنوات مع جدول توزيع منح (vest) يمتد أربع سنوات، حيث يتم vest بنسبة 25% بعد السنة الأولى والباقي بالتقسيط الشهري على مدى 36 شهراً. سعر ممارسة الخيار يساوي سعر إغلاق سهم كوجنت في تاريخ المنح، مع قيد الاستمرار في العمل حتى تواريخ vesting.
Cogent Biosciences（纳斯达克股票代码：COGT），一家专注于精准治疗的生物技术公司，已向 10名新员工授予诱导性股票奖励。公司薪酬委员会于2025年9月29日批准在公司2020年诱导计划下购买 299,200股普通股的期权。
这些期权的期限为10年，设有四年的归属计划，其中在第一年结束时有25%归属，余下部分在接下来的36个月内按月归属。行权价等于授予日 Cogent 的收盘价，前提是直到归属日仍然在职。
- None.
- None.
WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that on September 25, 2025, the Compensation Committee of Cogent’s Board of Directors, made up entirely of independent directors, approved the grants of “inducement” equity awards to 10 new employees under the company’s 2020 Inducement Plan with a grant date of September 29, 2025. The awards were approved in accordance with Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market.
The employees received, in the aggregate, nonqualified options to purchase 299,200 shares of Cogent common stock. Each option has a 10-year term, an exercise price equal to the closing price of Cogent’s common stock on the grant date, and a four-year vesting schedule with
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2/3 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.
Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653
FAQ
What type of equity awards did Cogent Biosciences (COGT) grant to new employees?
How many new employees received stock options from Cogent Biosciences?
What is the vesting schedule for Cogent Biosciences' September 2025 inducement grants?
When did Cogent Biosciences' Compensation Committee approve the inducement grants?
